Novartis AG: The Advancements & Challenges in Pelacarsen Development & Other Major Drivers! 

Novartis, a global pharmaceutical leader, reported its Q1 2025 results with impressive financial metrics combined with significant advancements in its pharmaceutical portfolio. The company’s operational metrics showcased robust performance, with net sales increasing by 15% and core operating income growing by 27%. This resulted in a core margin of 42.1%, up by 400 basis points, indicating effective cost management and revenue growth strategies. Free cash flow was notably strong at $3.4 billion, demonstrating Novartis’s effectiveness in converting core operating income into cash and supporting business reinvestment and shareholder returns.